Tag : ALK MUTATION

CONFERENCE UPDATE

Resectable NSCLC in transition: Integrating immunotherapy and targeted approaches
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.